GLP1R and chronic obstructive pulmonary disease: However, this gives a signal of a favorable effect of GLP-1 receptor agonist therapy in the COPD population, as was also previously shown in a similar study in the UK, where a 30% reduction per 100 person years of severe exacerbations was recorded in GLP-1 receptor agonist users compared to sulfonylurea users, as well as a 37% reduction per 100 person years of moderate exacerbations.